This Non-Interventional Study (NIS) is intended to evaluate the duration of treatment with an initial antidepressant taken as monotherapy in patients in whom treatment was changed because of suboptimal response at physician's discretion. This will address unmet medical needs of patients with a depressive episode related to RDD (ICD-10, Version 2010), who have failed to respond adequately to initial treatment with an antidepressant and contribute to an understanding of the usual approaches that physicians adopt to monitor initial treatment efficacy in RDD (Recurrent Depressive Disorder). The study will also focus on second-line therapy in hard to treat patients, describing the different pharmacotherapeutic strategies.
Study Type
OBSERVATIONAL
Enrollment
450
Research Site
Ivanovo, Russia
Research Site
Kazan', Russia
Research Site
Moscow, Russia
Research Site
Nizhny Novgorod, Russia
Research Site
Rostov-on-Don, Russia
Research Site
Saint Petersburg, Russia
Research Site
Stavropol, Russia
Research Site
Yaroslavl, Russia
Duration of treatment considered as time between initiation of antidepressant monotherapy and the alteration and/or augmentation of pharmacotherapy
Primary objective: The primary objective of this NIS is to evaluate the duration of treatment with an initial antidepressant taken as monotherapy in patients in whom treatment was changed because of suboptimal response at physician's discretion.
Time frame: up to 6 months
Pharmacotherapy strategy for the second line treatment
Distribution of the various pharmacotherapy strategies following suboptimal response: (switch; augmentation; combination of switch and augmentation and discontinuation of pharmacotherapy) among the patients population.
Time frame: up to 6 months
International Non-Proprietary Name (INN) of pharmacological agents prescribed for augmentation
Rate of the different pharmacological agents prescribed for augmentation; rout of their administration; mean and median duration of courses of treatment
Time frame: Up to 6 months
Doses of pharmacological agents used for augmentation
Mean and median doses of pharmacological agents used for augmentation
Time frame: Up to 6 months
Source of the patient's referral to a psychiatrist
Distribution of various sources of the patient's referral to a psychiatrist (psychotherapist; neurologist; internist; physician of other speciality; psychologist; came himself; other; and not known
Time frame: up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.